2.4 COPD, Bronchial Asthma & Pulmonary Embolism

COPD, Bronchial Asthma & Pulmonary Embolism

1. Obstructive Airway Disease: COPD vs Asthma Differential

Chronic Obstructive Pulmonary Disease (COPD) and Bronchial Asthma are characterized by airflow limitation, but differ fundamentally in etiology, inflammation, and reversibility.

High-Yield Clinical Entity ($\alpha_1$-Antitrypsin Deficiency): Consider $\alpha_1$-antitrypsin ($\alpha_1$-AT) deficiency in young non-smokers ($<45 \text{ years}$) presenting with COPD or liver cirrhosis. It causes panacinar emphysema predominantly affecting the lower lobes of the lung (unlike smoking-induced emphysema which is centrilobular and affects the upper lobes).

2. Chronic Obstructive Pulmonary Disease (COPD)

Clinical Phenotypes

• Chronic Bronchitis ("Blue Bloaters"): Defined clinically as productive cough for at least 3 consecutive months in 2 consecutive years. Characterized by mucus hypersecretion, cyanosis, hypoxemia, hypercapnia, pulmonary hypertension, and cor pulmonale (right heart failure with peripheral edema).
• Emphysema ("Pink Puffers"): Defined pathologically as permanent enlargement of airspaces distal to terminal bronchioles with wall destruction. Characterized by severe dyspnea, hyperinflated chest (barrel chest), decreased breath sounds, pursed-lip breathing, and weight loss.

GOLD Spirometric Staging (Based on Post-Bronchodilator $FEV_1$ % Predicted)

• GOLD 1 (Mild): $FEV_1 \ge 80\%$ predicted
• GOLD 2 (Moderate): $50\% \le FEV_1 < 80\%$ predicted
• GOLD 3 (Severe): $30\% \le FEV_1 < 50\%$ predicted
• GOLD 4 (Very Severe): $FEV_1 < 30\%$ predicted

Pharmacotherapy & GOLD ABE Assessment Group Management

• Group A (Low symptoms, 0-1 non-hospitalized exacerbations): Single bronchodilator (SABA, LABA, or LAMA).
• Group B (High symptoms mMRC $\ge 2$ or CAT $\ge 10$, 0-1 non-hospitalized exacerbations): Dual long-acting bronchodilator: LABA + LAMA (e.g., Tiotropium + Formoterol).
• Group E (Exacerbators: $\ge 2$ moderate exacerbations OR $\ge 1$ leading to hospitalization): LABA + LAMA. Add Inhaled Corticosteroid (ICS) if blood eosinophils $\ge 300 \text{ cells/}\mu\text{L}$ (forming Triple Therapy: LABA + LAMA + ICS).

Management of Acute COPD Exacerbation

1. Bronchodilators: Nebulized Short-Acting Beta-Agonist (Salbutamol $2.5-5 \text{ mg}$) + Short-Acting Muscarinic Antagonist (Ipratropium Bromide $0.5 \text{ mg}$).
2. Systemic Corticosteroids: Oral Prednisolone $40 \text{ mg}$ daily for 5 days (improves recovery and shortens hospital stay).
3. Controlled Oxygen Therapy: Administer via Venturi mask targeting $SpO_2$ of 88–92%.
   • RATIONALE (UPSC CMS Focus): In chronic severe hypercapnia, the central respiratory center becomes desensitized to high $PaCO_2$. Breathing is driven primarily by hypoxic drive detected by peripheral carotid bodies. Uncontrolled high-flow $O_2$ suppresses hypoxic drive and worsens V/Q mismatch via loss of hypoxic pulmonary vasoconstriction, precipitating severe hypercapnic coma ($PaCO_2 >80 \text{ mmHg}$).
4. Antibiotics: Indicated if 2 or more Anthonisen criteria are met (Increased Dyspnea, Increased Sputum Volume, Increased Sputum Purulence). Amoxicillin/Clavulanate or Macrolide for 5 days.
5. Non-Invasive Positive Pressure Ventilation (NIV / BiPAP): Indicated if acute hypercapnic respiratory acidosis ($pH < 7.35$ and $PaCO_2 > 45 \text{ mmHg}$) despite medical therapy.

---

3. Bronchial Asthma & GINA Guidelines

Pathophysiology & Triggers

Chronic airway inflammation driven by IgE mast-cell degranulation, eosinophil recruitment, airway hyperresponsiveness, smooth muscle spasm, and subepithelial basement membrane thickening.

GINA Guidelines Treatment Strategy (Track 1 - Preferred)

Current Global Initiative for Asthma (GINA) guidelines strictly discourage SABA-only treatment due to increased mortality and risk of severe exacerbations.

• Track 1 (Preferred Reliever): Uses Low-dose ICS-Formoterol as needed as the anti-inflammatory reliever (AIR) across ALL steps.
  • Step 1-2: As-needed low-dose ICS-Formoterol alone.
  • Step 3: Low-dose maintenance ICS-Formoterol + as-needed low-dose ICS-Formoterol (MART - Maintenance and Reliever Therapy).
  • Step 4: Medium-dose maintenance ICS-Formoterol + as-needed ICS-Formoterol.
  • Step 5: High-dose maintenance ICS-Formoterol + Add-on LAMA (Tiotropium) / Biologic agents (Omalizumab - anti-IgE, Mepolizumab - anti-IL5).

Acute Severe Asthma (Status Asthmaticus) Emergency Management

• Clinical Severity Red Flags: Inability to complete sentences in one breath, Silent chest (absence of wheezing due to severe lack of airflow), Cyanosis, Bradycardia, Exhaustion, $PEFR <33\%$ predicted.
• Critical Blood Gas Sign: A normal ($PaCO_2 \approx 40 \text{ mmHg}$) or elevated ($PaCO_2 >45 \text{ mmHg}$) level in a hyperventilating asthmatic patient is a dangerous sign of respiratory muscle fatigue and impending respiratory arrest (normally $PaCO_2$ should be low $\approx 25-30 \text{ mmHg}$ due to hyperventilation).
• Treatment: High-flow $O_2$ (target $SpO_2$ 93-95%), Continuous nebulized Salbutamol + Ipratropium, IV Hydrocortisone $200 \text{ mg}$ or Oral Prednisolone $50 \text{ mg}$, single dose IV Magnesium Sulfate $2 \text{ g}$ over 20 minutes for severe refractory obstruction.

---

4. Acute Pulmonary Embolism (PE)

Pathophysiology & Virchow's Triad

PE results from thrombi originating from deep vein thrombosis (DVT) of the lower extremities embolizing into the pulmonary arterial bed. Driven by Virchow's Triad: 1) Stasis, 2) Endothelial Injury, 3) Hypercoagulability.

Clinical Presentation

Sudden-onset dyspnea (most common symptom ~85%), pleuritic chest pain, tachypnea (>20/min), tachycardia (>100 bpm), hemoptysis, leg swelling (DVT), syncope (indicates massive PE).

Diagnostic Workup & Wells Score

• Wells Score Triage:
  • PE Unlikely ($\le 4.0$ points): Order High-Sensitivity D-Dimer. If negative ($<500 \text{ ng/mL}$), PE is ruled out without imaging (high negative predictive value). If positive, proceed to CTPA.
  • PE Likely ($>4.0$ points): Proceed directly to CT Pulmonary Angiography (CTPA) (Gold Standard diagnostic imaging test).

Diagnostic Pearls:

• V/Q Scanning: Indicated when CTPA is contraindicated (severe renal failure, IV contrast allergy, pregnancy).
• ECG Findings: Most common finding is Sinus Tachycardia. Classic but rare sign is the S1Q3T3 pattern (McGinn-White sign): Deep S wave in lead I, Q wave in lead III, Inverted T wave in lead III (<20% of cases). Right axis deviation and incomplete/complete RBBB reflect acute right heart strain.

Treatment Protocol

• Hemodynamically Unstable (Massive PE with Shock / SBP <90 mmHg):
  • Immediate Thrombolysis with IV Alteplase (tPA 100 mg over 2 hours) or Tenecteplase. Surgical embolectomy if thrombolysis is contraindicated.
• Hemodynamically Stable (Submassive / Low Risk):
  • Immediate Anticoagulation: Low Molecular Weight Heparin (Enoxaparin $1 \text{ mg/kg}$ SC bid) or Unfractionated Heparin (UFH) bridged to Direct Oral Anticoagulants (Rivaroxaban $15 \text{ mg}$ bid for 3 weeks then $20 \text{ mg}$ daily, or Apixaban) or Warfarin (target INR 2.0–3.0) for at least 3 to 6 months.